ReviewFrontiers in medicine2026
Electroacupuncture in the treatment of non-alcoholic fatty liver disease: mechanistic insights and therapeutic potential.
Review in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-alcoholic fatty liver disease (NAFLD) has become the most prevalent chronic liver disorder globally, driven by increasing rates of obesity, insulin resistance, and metabolic dysfunction. In the absence of approved pharmacological therapies, electroacupuncture (EA) has garnered attention as a promising adjunctive intervention. This review synthesizes recent advances in understanding the mechanistic underpinnings and therapeutic potential of EA in NAFLD. We discuss how EA modulates hepatic lipid metabolism, insulin signaling, inflammation, fibrosis, and autophagy through key molecular pathways, including AMPK, SIRT1, PI3K/Akt, and NF-κB. Preclinical studies and emerging clinical trials indicate that EA effectively improves hepatic steatosis, metabolic parameters, and liver function with minimal side effects. Collectively, these findings underscore EA as a promising strategy for NAFLD treatment and highlight the need for further translational research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.